TULSA-PRO® (Transurethral Ultrasound Ablation) is an innovative, minimally invasive treatment for localized prostate cancer that offers a compelling alternative to traditional surgery. Utilizing real-time MRI guidance, TULSA-PRO delivers precise, directional ultrasound energy through the urethra to ablate cancerous prostate tissue while actively protecting surrounding structures like the urethra, rectum, and neurovascular bundles. This targeted approach enables physicians to customize treatment plans based on individual prostate anatomy and disease characteristics, aiming to minimize side effects and preserve quality of life. The procedure is incision-free, radiation-free, and typically performed on an outpatient basis, allowing for a quicker recovery compared to conventional surgical methods.


Clinical studies have demonstrated that TULSA-PRO achieves oncological outcomes comparable to radical prostatectomy, with significantly lower rates of urinary incontinence and erectile dysfunction. Five-year data from the TACT trial revealed an 86% biochemical recurrence-free survival rate and a 99% overall survival rate among patients with low- to intermediate-risk prostate cancer. Importantly, 92% of patients achieved pad-free continence, and 87% maintained erections sufficient for intercourse at five years post-treatment. These results suggest that TULSA-PRO can effectively eradicate prostate cancer while preserving urinary and sexual function, offering a promising treatment option for men seeking to maintain their quality of life.